Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO)

Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO)

Abstract Background The identification of homologous recombination deficient (HRD) tumor is now a crucial step for the therapeutic management of ovarian cancer. The HRD tumors are both sensitive to olaparib maintenance treatment and to platinum-based chemotherapy. Despite the large amount of HRD tes...

Full description

Saved in:
Bibliographic Details
Main Authors: Raphaël Leman, François Cherifi, Marianne Leheurteur, Pierrick Theret, Camille Pasquesoone, Mathilde Saint-Ghislain, Lucie Bresson, Christophe Denoyelle, Nicolas Vigneron, Laurent Poulain, Raphaël Delepee, Benoit Berby, Julie Dremaux, Aurélie Dumont, Cécile Blanc-Fournier, Corinne Jeanne, Mélanie Briand, Nathalie Rousseau, Louis-Ferdinand Pepin, Elodie Deruche, Fabienne Dumont, Alexandra Leconte, Justine Lequesne, Bénédicte Clarisse, Florence Joly, Laurent Castera, Roman Rouzier
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
Molecular biology
Ovarian cancer
Homologous recombination deficiency
Platinum resistance
Online Access:https://doi.org/10.1186/s12885-025-14423-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14423-2

Similar Items